- Telehealth Visits
- Insurance plan information
Katy K. Tsai, MD
Cutaneous (Skin) Medical Oncology- Telehealth Visits
- Insurance plan information
Katy K. Tsai, MD
Cutaneous (Skin) Medical Oncology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Katy K. Tsai is a medical oncologist who specializes in treating melanoma and other skin cancers.
In addition to caring for patients, Tsai conducts clinical trials with two of her colleagues in cutaneous oncology, Dr. Adil Daud and Dr. Alain Algazi, seeking new and better therapies for patients with advanced melanoma or head and neck cancers. She also has a long-standing research interest in quality of life and outcomes for patients receiving immunotherapy.
Tsai graduated with a degree in comparative literature from Brown University before earning her medical degree from Brown. She completed a residency in internal medicine at the University of North Carolina at Chapel Hill, followed by a fellowship in medical oncology at UCSF, where she served as chief fellow.
Tsai is a member of the American Society of Clinical Oncology. She was born in Taiwan and raised in Toronto.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Oncology, University of CA at San Francisco - Hema/Onc GME
Residency
- Internal Medicine, University of North Carolina Schl of Medicine GME
Internship
- Internal Medicine, University of North Carolina Schl of Medicine GME
Degree
- MD, Brown University School of Medicine
My expertise
Specialties
Locations
My research
Clinical trials
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaOpens in a new window
Recruiting
Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be est...Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid MalignanciesOpens in a new window
Recruiting
To identify dose limiting toxicities [DLT] with GIM-122Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsOpens in a new window
Recruiting
To assess incidence and severity of AE / SAEs and tolerability assessed by CTCAE gradingVO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]Opens in a new window
Recruiting
Time from the date of randomization to death due to any cause
Publications
Showing 1-6 of 55 reviews
- March 26, 20265 out of 5 Stars
Earlier I had a pet scan and she didn't have the complete results yet and she took the time to look at previous scan and current scan that was available and said she doesn't notice anything but can't give me any other true report until radiology sends one and she would let me know. The next day she did let me know. How awesome she is
- March 20, 20265 out of 5 Stars
Dr Tsai always goes over and above to look at my tests. She even got a review by the tumor board radiologist regarding a question I had on my pet scan interpretation.
- March 9, 20265 out of 5 Stars
Exceptional care
- February 15, 20265 out of 5 Stars
Dr Tsai is a wonderful doctor. She explained things clearly, listened to my concerns and instilled confidence.
- January 15, 20265 out of 5 Stars
Good
- December 29, 20255 out of 5 Stars
Consistent and considerate care
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.